A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Wang, Ting
Huang, Lu Li Lin
Liu, Jie Wei
Zhu, Da Xing
Dong, Jing Si
Deng, Han Yu
Zheng, Xi
Tian, Long
Jiang, Li Li
Wang, Wei Ya
Zhou, Ping
Su, Ming Gang
Pu, Dan
Cai, Xu Yu
Feng, Ming Yang
Ou, Xue Jin
Wang, Yongsheng
Zhou, Qing Hua
机构：
[1] Sichuan Univ, West China Hosp, Dept Thorac Surg, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Nucl Med, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Ctr Canc, Thorac Oncol Ward, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8024
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase II Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients (pts) with Resectable Non Small Cell Lung Cancer (NSCLC)
    Owen, Dwight
    Bunn, Paul, Jr.
    Johnson, Bruce
    Kwiatkowski, David
    Kris, Mark
    Wistuba, Ignacio
    Gandhi, Mayank
    Phan, See
    Shames, David
    Schulze, Katja
    Bernaards, Coen
    Aisner, Dara
    Chaft, Jamie
    Gainor, Justin
    Lee, Jay
    Minna, John
    Mino-Kenudson, Mari
    Garcia-Prieto, Celia
    Rusch, Valerie
    Sabichi, Anita
    Villaruz, Liza
    Wozniak, Antoinette
    Carbone, David
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1082 - S1082
  • [42] RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)
    Yue, D.
    Wang, W.
    Liu, H.
    Chen, Q.
    Chen, C.
    Liu, L.
    Zhang, P.
    Zhao, G.
    Yang, F.
    Han, G.
    Cheng, Y.
    Yu, B.
    Yang, Y.
    Chen, H.
    Jiang, J.
    Yao, B.
    Wang, S.
    Wang, R.
    Zheng, W.
    Wang, C.
    ANNALS OF ONCOLOGY, 2024, 35 (03) : 332 - 333
  • [43] Cisplatin and gemcitabine (GC) as neoadjuvant therapy of stage III unresectable non-small cell lung cancer (NSCLC):: A phase II study
    Mazzoni, F
    Di Stefano, A
    Maestri, A
    Calandri, C
    Mosconi, AM
    De Marinis, F
    Scagliotti, GV
    Selvaggi, G
    Crinò, L
    Tonato, M
    ANNALS OF ONCOLOGY, 2000, 11 : 8 - 8
  • [44] Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study
    Ma, Zhanming
    Fu, Fangqiu
    Zhang, Yang
    Chen, Haiquan
    LUNG CANCER, 2025, 201
  • [45] Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer
    De Marinis, Filippo
    Gebbia, V.
    De Petris, L.
    ANNALS OF ONCOLOGY, 2005, 16 : 116 - 122
  • [46] Neoadjuvant Chemotherapy with Gemcitabine and Cisplatin in Stage IIIA/B Non-Small Cell Lung Cancer
    Maximiliano Van Kooten
    Moisés Rosenberg
    Mauro Orlando
    José Morero
    Manuel Vilanova
    Oscar Rojas
    Héctor Vicente
    Claudia Bagnes
    Carlos Silva
    Reinaldo D. Chacón
    Investigational New Drugs, 2002, 20 : 439 - 446
  • [47] Neoadjuvant chemotherapy with gemcitabine and cisplatin in stage IIIA/B non-small cell lung cancer
    Van Kooten, M
    Rosenberg, M
    Orlando, M
    Morero, J
    Vilanova, M
    Rojas, O
    Vicente, H
    Bagnes, C
    Silva, C
    Chacón, RD
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (04) : 439 - 446
  • [48] Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus chemotherapy for potentially resectable non-small cell lung cancer: A phase Ib study
    Ding, Naixin
    Zhao, Lijun
    Zhang, Shuai
    Qiu, Ninglei
    Song, Xue
    Kong, Cheng
    Jiang, Ning
    Zhao, Yang
    Huang, Jianfeng
    Jiang, Feng
    Jiang, Ming
    Zhu, Zihao
    Yin, Rong
    Ren, Binhui
    Zhu, Xiangzhi
    Li, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] A phase Ib trial of neoadjuvant chemoradiotherapy and durvalumab (MEDI4736) for potentially resectable stage III non-small cell lung cancer (NSCLC)
    Ahn, B. C.
    Lee, S.
    Seo, J. W.
    Lee, C. Y.
    Lee, J. G.
    Park, S. Y.
    Kim, D. J.
    Lee, C. G.
    Cho, J.
    Yoon, H. I.
    Shim, B. Y.
    Cho, D. G.
    Kim, S. W.
    Park, H. S.
    Chun, Y. J.
    Hong, M. H.
    Kim, H. R.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2019, 30 : 601 - 601
  • [50] Neoadjuvant tislelizumab or placebo plus platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non-small cell lung cancer (NSCLC): A phase III trial in progress
    Wang, C.
    Wang, R.
    Ma, Y.
    Liang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S746 - S746
12345